Chargement des cours...
Prévisions
Aucune donnée d'analyste n'est disponible pour cette entreprise.
Discussions dans la communauté
Il n'y a pas encore de discussion sur cet actif.
Lancer une discussionActualités Accéder au fil d'actualités
Bonesupport surges after CMS decision for CERAMENT G and expects strong growth
Bonesupport’s stock rose about 35% within a month, supported by improved reimbursement in the US from CMS for the antibiotic-containing bone substitute CERAMENT G. Analysts at ABG Sundal Collier expect an organic sales increase of 31% for Q1; results will be published on April 22. CEO Torbjörn Sköld confirms the 2026 guidance of more than 35% revenue growth, driven by further market penetration in foot/ankle, trauma and revision arthroplasty. Technically, the stock has moved above the 200-day moving average; investors are holding positions and betting on strong quarterly figures. » Plus sur deraktionaer.de
Bonesupport targets at least 35% revenue growth in 2026 after strong Q4
Bonesupport reports a Q4 2025 revenue increase of 36% to SEK 313 million and records a sales increase of nearly 40% for 2025 overall. The company issues guidance for 2026 of at least 35% revenue growth at constant exchange rates and cites strong demand in the US for CERAMENT products as well as potential from indication expansions. Gross margins are typically around 90%; the stock rises by almost 20% after the outlook and reaches its highest level since October. » Plus sur deraktionaer.de
Bonesupport records strong revenue and margin growth, shares fall after quarterly results
Bonesupport reported Q3 2025 net sales of SEK 294.1m (+24% yoy; +34% currency-adjusted) and an adjusted operating margin of 27%, driven by a strong US business and growth in the antibiotic-releasing CERAMENT products. Operating cash flow remained robust and net cash stood at SEK 379.0m at quarter-end. The company is preparing market entries in spine surgery and revision arthroplasty, received NTAP approval for CERAMENT G and reiterated full-year guidance of >40% currency-adjusted revenue growth. Despite operational progress, the stock fell sharply after the presentation, reflecting investor concerns about currency headwinds, possible regulatory hurdles and market risks. » Plus sur de.investing.com
Bonesupport achieves record profitability and currency-adjusted revenue growth of 40% in Q2 2025
Bonesupport reports net sales of SEK 284m for Q2 2025 (+29% y/y; +40% currency-adjusted) and adjusted operating income of SEK 62m, the highest margin in the company’s history (EBIT margin 26%). The North American market drives growth (SEK 236m, +36% or +49% currency-adjusted), led by CERAMENT G with USD 18.3m in sales (+84%). Operating cash flow was SEK 50m; the company targets currency-adjusted revenue growth of over 40% for 2025 and plans to launch CERAMENT BVF for spinal applications in North America in December 2025. » Plus sur de.investing.com
Bonesupport Holding AB reports strong revenue growth in the second quarter of 2025
Bonesupport Holding AB recorded a 29% increase in revenue to SEK 284.4 million in the second quarter of 2025, with a stable gross margin of around 95%. The US market showed particularly strong growth, with Cerement G sales rising by 84%, while the company reaffirmed its outlook for continued revenue growth. Despite regulatory and market challenges, the outlook remains positive, supported by product innovation and strategic expansion. » Plus sur de.investing.com
Dividendes historiques Dividendes
Tous les indicateurs de dividendes Tous les indicateursDonnées financières de l'entreprise
| (EUR) | septembre 2026 | YoY |
|---|---|---|
| Chiffre d'affaires | 36,06 M | 35,51 % |
| Bénéfice brut | 33,17 M | 34,18 % |
| Bénéfice net | 8,15 M | 160,94 % |
| EBITDA | 10,47 M | 68,69 % |
Données fondamentales
| Indicateur | Valeur |
|---|---|
Capitalisation boursière | 1,86 Md € |
Nombre d'actions | 65,22 M |
Plus haut/bas sur 52 semaines | 30,44 € - 15,03 € |
| Dividendes | Non |
Bêta | 0,49 |
Ratio P/E | 77,14 |
Ratio PEG | 0,98 |
Ratio P/B | 20,98 |
Ratio P/S | 14,83 |
Profil de l'entreprise
Bonesupport Holding AB (publ), une entreprise d'orthobiologie, développe et commercialise des substituts de greffe osseuse biocéramiques injectables destinés au traitement des cavités osseuses en Europe, en Amérique du Nord et à l'international. La société propose CERAMENT Bone Void Filler, un comblement osseux synthétique injectable, modelable et perçable, qui comprend de l'hydroxyapatite, du sulfate de calcium et l'agent de contraste radiologique iohexol ; CERAMENT G, un substitut de greffe osseuse céramique injectable à la gentamicine ; et CERAMENT V, un comblement osseux synthétique injectable à la vancomycine. Elle développe également des candidats-produits précliniques destinés à favoriser la repousse osseuse, axés sur les traumatismes, la reprise d'arthroplastie, l'ostéomyélite chronique, la reprise d'arthroplastie, l'oncologie, ainsi que les infections osseuses et du pied liées au diabète. La société a été fondée en 1999 et son siège social se trouve à Lund, en Suède.
| Nom | Bonesupport Holding |
| PDG | Torbjorn Skold |
| Siège social | Lund,
sn Suède |
| Site web | |
| Secteur | Santé |
| Industrie | Biotechnologie |
| Introduction en bourse | 14/12/2017 |
| Employés | 160 |
Symboles boursiers
| Bourse | Symbole |
|---|---|
Sto | BONEX.ST |
London Stock Exchange | 0RQO.L |
XETRA | 2B4.F |
Pnk | BOEUF |
Frankfurt | 2B4.F |
Düsseldorf | 2B4.DU |
London | 0RQO.L |
Stockholm | BONEX.ST |
München | 2B4.MU |